Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome.
AbstractMyeloperoxidase (MPO) and paraoxonase-1 (PON1) are inflammatory and anti-inflammatory enzymes, respectively that have been involved in the pathogenesis of coronary artery disease (CAD). In this study we sought to evaluate the relations of MPO and PON1 with high density lipoprotein (HDL) mean size in patients with acute coronary syndrome (ACS). Collectively, 50 control subjects and 50 patients with ACS were participated in this study. MPO level and PON1 activity was determined using immunoassay and colorimetric methods, respectively. HDL mean size was determined by a dynamic light scattering methodology. Other clinical risk factors were also determined by standard methods. The MPO/PON1 ratio amount was significantly higher in patients with ACS (1.49±1.10) than in control subjects (0.21±0.14) (P<0.01). There was a significant correlation between MPO/PON1 ratio and HDL mean size in patients with ACS. Amount of the enzymes and their relations to HDL particle size in patients with ACS may play a part in the pathogenesis of ACS. Also, MPO/PON1 ratio may be a robust predictor of ACS.
Labarthe DR. Epidemiology and prevention of cardiovascular diseases: a global challenge. 2nd ed. Massachusetts: Jones & Bartlett Publishers; 2011.
Weissberg PL, Bennett MR. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340(24):1928-9.
Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4): 1381-478.
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77(5):598-625.
Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25(6):1102-11.
Vaisar T. Proteomics Investigations of HDL: Challenges and Promise. Curr Vasc Pharmacol 2012; 10(4):410-21.
Kontush A, Chapman MJ. Functionally defective highdensity lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58(3):342-74.
Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006;187(1):74-81.
Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA2008;299(11):1265-76.
Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006;21(4):322-8.
Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 2002;277(35):32172-9.
Deakin S, Moren X, James RW. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol 2007;27(5):1146-52.
Kontush A, Chapman MJ. Antiatherogenic small, dense HDL guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3(3):144-53.
Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23(10):1881-8.
Sakuma N, Yoshikawa M, Hibino T, Ohte N, Kamiya T, Kunimatsu M, Kimura G, Inoue M. HDL3 exerts a more powerful antiperoxidative and protective effect against peroxidative modification of LDL than HDL2 does. J Nutr Sci Vitaminol (Tokyo) 2002;48(4):278-82.
Shuhei N, Söderlund S, Jauhiainen M, Taskinen MR. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis 2010;9:104.
El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, Otvos JD, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 2009;150(2):84-93.
Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 2009;50(4):716-22.
Beltowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism forproatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170(1):21-9.
Lima ES, Maranhão RC. Rapid, Simple Laser-Light- Scattering Method for HDL Particle Sizing in WholePlasma. Clin Chem 2004;50(6):1086-8.
Fernandes MX, Santos NC, Castanho MA. Continuous particle size distribution analysis with dynamic light scattering: MAXAMPER: A regularization method using the maximum amplitude for the average error and theLagrange's multipliers method. J Biochem Biophys Methods 1998;36(2-3):101-17.
Thomas JC. The determination of log normal particle size distributions by dynamic light scattering. J Colloid Interface Sci 1987;117(1):187-92.
Lixia Y, Feng Q, Ruiwei G, Xianmei W, Chuanming G. e0379 Study of correlationship between myeloperoxidase paraoxonase and coron. Heart 2010;96:A117-A118.
Samsamshariat SZ, Basati G, Movahedian A, Pourfarzam M, Sarrafzadegan N. Elevated plasma myeloperoxidaselevels in relation to circulating inflammatory markers in coronary artery disease. Biomark Med 2011;5(3):377-85.
Jornayvaz FR, Brulhart-Meynet MC, James RW.Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009;19(9):613-9.
Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW, Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM. Both paraoxonase- 1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One 2009;4(8):e6809.
Rye KA, Duong MN. Influence of phospholipid depletion on the size, structure, and remodeling of reconstituted high density lipoproteins. J Lipid Res 2000;41(10):1640-50.